急性脑梗死重组组织型纤溶酶原激活物静脉溶栓后严重出血性转化研究进展

Advances in severe hemorrhagic transformation after intravenous thrombolysis with recombinant tissue plasminogen activator for acute brain infarction

严重出血性转化是静脉溶栓治疗最危险的并发症。本文对近年来有关静脉溶栓后严重出血性转化的定义、临床表现、影像学特征以及相关危险因素的研究进展进行综述。对具有严重出血性转化高风险的急性脑梗死患者可以选择低剂量重组组织型纤溶酶原激活物(recombinant tissue plasminogen activator,rtPA)静脉溶栓治疗,以降低症状性颅内出血的发生风险。

Severe hemorrhagic transformation is a most dangerous complication during thrombolytic therapy for acute ischemic stroke.This paper summarizes the definition,clinical manifestations,imaging characteristics,and the related risk factors of thrombolysisassociated severe hemorrhagic transformation.In acute ischemic stroke patients with high risk of severe hemorrhagic transformation,thrombolytic therapy with a low dose of recombinant tissue plasminogen activator(rt PA) may reduce the risk of symptomatic intracerebral hemorrhage.